logo
The struggle to access weight-loss jabs from NHS

The struggle to access weight-loss jabs from NHS

Independenta day ago
Thousands of obese patients in England are unable to access the weight loss jab Mounjaro due to a 'postcode lottery' in NHS provision.
Data obtained by Sky News reveals only 8 of 42 NHS Integrated Care Boards (ICBs) in England are currently able to provide the treatment, despite its intended availability from 23 June.
Doctors warn patients are being 'set up for failure', with claims that NHS England has only funded treatment for a fraction of the 97,500 patients NICE calculated should be treated in the first year.
NHS England stated it has 'fully supported the rollout', issuing guidance and providing funding to ICBs in March to cover treatment costs and support services.
Concerns also exist regarding post-treatment support, with NICE stressing the need for structured follow-up for NHS patients to prevent weight regain, a service not available to the 1.5 million private users.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust
Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust

The Independent

time7 minutes ago

  • The Independent

Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust

More than 20 patients who say their quality of life was wrecked when they were needlessly given a highly toxic cancer drug are suing the NHS trust involved. Some people were prescribed temozolomide – which should normally be used for only six months – for more than a decade during treatment by the University Hospitals Coventry and Warwickshire NHS Trust. They say the overprescribing left them with side-effects including secondary cancers and crippling fatigue. Earlier this year the Care Quality Commission was looking into at least 14 cases, but lawyers say more are emerging all the time. An investigation by lawyers Brabners found that, over the past two decades, numerous patients with brain and spinal tumours under the care of Professor Ian Brown were routinely exposed to prolonged and in some cases 'unnecessary' use of the chemotherapy drug, which has severe side-effects including extreme fatigue, confusion, sickness and seizures. The time periods temozolomide was given for allegedly ran contrary to medical and scientific guidelines. Standard NHS procedure is to use the drug over six months, and the drug manufacturer advises it be used for up to 12 months. One man said he was prescribed it for nearly two years longer than necessary, suffering extreme fatigue and low mood as a result. A woman in her twenties said she was misdiagnosed with cancer, receiving the drug needlessly for about eight years. Some patients are now having treatment for secondary cancers allegedly linked to overuse of temozolomide, the lawyers claim. Others claimed its prolonged use left them unable to pursue career ambitions and normal day-to-day activities because the chemotherapy was debilitating, with a long recovery time. Some reported loss of fertility or abnormal blood test results. The legal team says data shows that the trust's spending on the drug of £3.6m from 2009 to 2024 is 10 times that of other NHS oncology departments. The lawyers are now calling for an extended patient safety review and independent investigation, focusing in particular on treatment received by patients under Prof Brown dating back to 2006. The trust has been conducting an internal patient safety review, covering 2017 to 2023, when Prof Brown retired. A patient who identified only as Michael received an extra 22 cycles of temozolomide at the trust, despite his scans being stable. Prof Brown was not present during consultations, and Michael said he was always seen by a clinical nurse specialist. After suffering extreme fatigue and low mood, he learnt through news reports of mistreatment –not from the trust – that he should not have remained on treatment for so long, according to his lawyers. Another patient, identified only as Becky, says she received at least 100 cycles of the drug unnecessarily after being misdiagnosed with a brain tumour. Fiona Tinsley, head of medical negligence at Brabners, said: 'The extent of this scandal, and the physical and mental impact it has had on Prof Brown's patients cannot be underestimated.' She added: 'We believe there are many more patients out there who haven't yet come forward and some who may have sadly passed away. 'While we welcome the ongoing investigations being undertaken by the General Medical Council and Royal College of Physicians, we believe a full independent inquiry is necessary – including an extension of the trust's own review back to 2006 – not only to ensure justice for victims, but that processes are put in place to better identify and prevent such failings happening again.' A spokesperson for the trust told The Independent: 'We have comprehensively reviewed and spoken to all individuals who were receiving temozolomide (TMZ) treatment at the end of 2023 to ensure appropriate support and care plans are in place. 'A glioblastoma is an aggressive brain tumour with fewer than two per cent of patients surviving longer than 10 years. This is an extremely complex condition and all modes of treatment – surgery, chemotherapy and radiotherapy – carry the risk of complications and side-effects. 'National Institute for Health and Care Excellence (Nice) guidelines recognise that clinicians can exercise professional judgment appropriate to individual circumstances when offering treatment to patients. 'We have commissioned the Royal College of Physicians to conduct an independent review of a representative cohort of patients who received greater than 12 cycles of adjuvant TMZ between 2017 and 2023. 'As this process is ongoing, it would be inappropriate to comment further at this stage." It's understood that CQC inspectors have been in touch with the trust to understand the details, and seek assurances that patients are not at risk. The regulator will be reviewing more information to judge whether it needs to be involved.

The priming skin serum that banishes breakouts to leave skin glowing - and it uses a VERY unique ingredient: 'My skin has never looked so clear'
The priming skin serum that banishes breakouts to leave skin glowing - and it uses a VERY unique ingredient: 'My skin has never looked so clear'

Daily Mail​

time37 minutes ago

  • Daily Mail​

The priming skin serum that banishes breakouts to leave skin glowing - and it uses a VERY unique ingredient: 'My skin has never looked so clear'

Daily Mail journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission - learn more Clear skin can be difficult to achieve, especially if you have blemishes. You might find that you're either dealing with a breakout or the marks left behind. Both of those concerns are a job for the 47 Skin Anti-Blemish and Scar Repair Serum. This powerful serum takes no prisoners, working on contact to kill off 99.9 percent of the bacteria responsible for blemishes. There's nothing else like it, and it's all thanks to the unique compound known as Silver Chitoderm. 47 Skin Anti-Blemish and Scar Repair Serum Bacteria can run rampant on your skin, causing stubborn breakouts that are difficult to control. This serum works like a dream, killing 99.9 percent of them to leave skin clearer and brighter. In addition to reducing blemishes and marks, it also imparts moisture to give your skin a softer feel. You can even use it as a makeup primer! The results are astonishing, with many users sharing their impressive before and after results. Buy here Shop The brand harnessed the protective and healing properties of silver and coupled them with Chitoderm, which is formulated to create a protective and supportive barrier on the surface and essentially keep the silver right where it needs to be. Because the silver is concentrated right where you need it, it can target those unwanted marks with precision. Whether your concern is a blemish or a spot, you can rely on it to eradicate the bacteria and leave skin calmer and clearer. According to Dr. Sunil Chopra, a consultant dermatologist who founded the London Dermatology Centre, 'It decreases the production of melanin, which is often elevated in scars, reducing pigmentation over time.' And, unlike so many other treatments formulated to minimize those marks, 47 Skin's formula won't leave skin feeling tight and parched. In fact, it has the opposite effect thanks to ingredients like shea butter that soften skin to leave it feeling smoother and looking plumper. The beauty of the formula is that it works overtime, even doubling as a primer for makeup. That's key, because if you regularly wear makeup, you know how helpful primer can be — but very few offer the powerhouse skin care benefits that this serum delivers. The proof is in the consumer studies consisting of over 9,300 participants. Of those, a whopping 94 percent said they would buy the serum again, while 92 percent experienced a reduction in their spots. A whopping 90 percent said they had fewer scars, too. It's proven so effective that users have shared jaw-dropping before and after images revealing clarity and a brighter complexion. 'This is an excellent product. It has really smoothed out my complexion. The delivery was quick to boot. Very pleased,' raved one shopper. 'The acne has visibly decreased, as have my scars and uneven skin tone,' shared another. 'Overall it just looks so much better.' A third customer summed it up perfectly, stating: 'My skin has never looked so clear.' If you're chasing results like those, the 47 Skin Anti-Blemish and Scar Repair Serum could be just what your routine needs!

More than 400 indirect deaths linked to LA wildfires, study suggests
More than 400 indirect deaths linked to LA wildfires, study suggests

BBC News

time38 minutes ago

  • BBC News

More than 400 indirect deaths linked to LA wildfires, study suggests

More than 400 additional deaths are estimated to be linked to the wildfires that ravaged Los Angeles earlier this year, according to a new study. The figure, published on Wednesday in the medical journal JAMA, looks at deaths that have been attributed to factors caused by the wildfires, like poor air quality and delays in accessing is a higher figure than the official death count of 31 by the Los Angeles County, which tallied deaths caused directly by the study comes as hundreds of wildfires burn across the US and Canada, prompting air quality advisories in cities like Chicago, Buffalo and New York. The Palisades and Eaton fires tore through Los Angeles in January, destroying thousands of structures and leading to the evacuation of more than 100,000 Los Angeles wildfires are becoming faster and more furiousThe far-reaching impacts of wildfire smoke – and how to protect yourselfThe latest study revealed that around 440 people are estimated to have died as a result of the wildfires between 5 January and 1 February. Researchers said they tallied the figure by looking at all deaths and their causes in Los Angeles during the period of the fires, and comparing it to similar data from previous results show that there were nearly 7% more deaths during the wildfires. Some are attributed to lung and heart conditions exacerbated by smoke or stress, while others are more indirect - like delayed healthcare treatment for dialysis or cancer patients as a result of fire-related authors said that the findings underscore the need for officials to count both direct and indirect fatalities of wildfires and other climate-related emergencies when trying to quantify their impact. "They also highlight the need for improved mortality surveillance during and after wildfire emergencies," the authors said, noting that their figures are provisional as there may have been additional fire-related deaths beyond the scope of the BBC has reached out to Los Angeles County officials for comment on the study's findings. Another study released on Wednesday in JAMA that looked at the aftermath of the 2023 Maui wildfires showed that 22% of adults in the region had reduced lung function, and half displayed symptoms of depression. The fires, which broke out in August 2023 and were the worst to affect Hawaii in recent history, killed at least 102 people and destroyed more than 2,000 structures. The authors of the Maui study said their results show the need for "sustained clinical monitoring and community-based mental health supports" months after a climate disaster.A second study on the Hawaii fires suggests that Maui saw the highest suicide and drug overdose rates in the month of the 2023 have become more frequent in recent years as a result of climate change, driven by hotter and drier weather that fuels fire addition to directly threatening lives and structures, smoke from wildfires has been shown to have adverse health effects on smoke has been found to be harmful to certain immune cells in the lungs, with a toxicity four times greater than particulates from other types of pollution. This can have a long-term impact on cardiovascular health, experts have people, pregnant women and young children, as well as those with underlying health conditions, such as heart disease or asthma, are more likely to get sick, experts say. But the smoke can also impact healthy adults.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store